Context: Chia seed is a popular dietary supplement, taken mainly for its high content of alpha-linolenic acid, vegetable protein, and dietary fiber, yet information about its clinical effects is lacking. Objective: This review aims to summarize the clinical evidence regarding the use of chia seed for a wide variety of health conditions. Data Sources: A number of databases, including PubMed and Embase, were searched systematically. Study Selection: Randomized controlled trials that assessed the clinical effects of chia seed consumption in human participants were included. The quality of trials was assessed using the Cochrane Risk of Bias Tool. Data Extraction: Data on study design, blinding status, characteristics of participants, chia seed intervention, comparator, clinical assessment, duration of intake, interval of assessment, and study funding status were extracted. Meta-analysis was performed. Results: Twelve trials were included. Participants included healthy persons, athletes, diabetic patients, and individuals with metabolic syndrome. Pooling of results showed no significant differences except for the following findings of subgroup analysis at higher doses of chia seed: (1) . The quality of all evidence assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was low or very low. All trials employed only surrogate markers as outcomes. Conclusions: Future trials with improved methodological quality, welldescribed clinical events, and validated surrogate markers as outcomes are needed to support the potential health benefits of chia seed consumption. Systematic Review Registration: PROSPERO registration no. CRD42015029990. 
INTRODUCTION
Chia seed, or Salvia hispanica L., is the seed of a summer herbaceous plant belonging to the Lamiaceae (mint) family. 1, 2 The use of chia seed can be traced back to the pre-Columbian era, when chia seed was not only consumed as a food but was also used as a medicine and as an offering to the Aztec gods. 1 Today, chia seed is popularly consumed as a functional food 3 in many different forms, including chia fresca (ie, chia seeds mixed with a beverage), 1 baked items, cereal bars, etc.
surrogate marker (eg, blood cholesterol level for cardiovascular disease, blood sugar level for diabetes). The clinical effect in any health setting (investigated using either clinical events or surrogate markers) was the primary outcome of interest. In addition, any adverse effect (eg, gastrointestinal disturbance) reported in the trials was considered the secondary outcome of interest.
Study quality assessment
The methodological quality of each trial was assessed by 2 authors (S.L.T. and P.V.) independently using the Cochrane Risk of Bias Tool. 15 The domains for methodological evaluation using the Risk of Bias Tool include sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting (assessed by comparing reported results with outcomes listed in the Methods section), and other sources of bias. 15 The funding of the trials was assessed within the domain of "other sources of bias." Each trial was classified as having low risk (low risk of bias for all domains), high risk (high risk of bias for 1 or more domains), or unclear risk (unclear risk of bias for 1 or more key domains, given no high risk of bias in any domain).
Data analysis
To determine the clinical effect of chia seed on continuous outcomes, the results were expressed as mean differences (MDs) with 95%CIs. For any clinical assessment, the change in outcome from baseline was compared between the chia seed group and the comparator group. Any missing data was requested from the author directly. Data from trials were pooled in a meta-analysis by 2 authors (S.L.T. and P.V.) independently, using the inverse-variance method with a random-effects model. 17 Heterogeneity of the included trials was assessed using the chi-squared test and the I 2 test. For the chi-squared test, P 0.10 indicated statistically significant heterogeneity. 15 An I 2 value of more than 50% indicated substantial heterogeneity. 15 In cases of substantial heterogeneity, subgroup analysis was performed to explore possible sources of heterogeneity.
In addition, subgroup analysis was conducted for trials with homogenous characteristics specified a priori. Specifically, to examine the effect when different doses of chia seed were used, all trials that used similar doses of chia seed were grouped together and compared between each subgroup of low, medium, and high doses of chia seed. Similarly, to examine the effect of chia seed on participants with different health conditions, trials that recruited participants with similar health conditions were grouped together and compared against trials that recruited healthy adults. When a different comparator was used, trials that used similar comparators were grouped together and compared against trials that used active and nonactive comparators. When different types of chia seed were used, trials that used similar types of chia seed were grouped together and compared against trials that used non-Salba chia seed and Salba chia seed. When different forms of chia seed were used, trials that used similar forms of chia seed were grouped together and compared against trials that used whole chia seed and ground chia seed. For the dosage of chia seed, trials were categorized according to the 2 trials 6, 8 included in this review that categorized doses as follows: (1) low dose when consumption was less than or equal to 7 g of chia seed daily; (2) medium dose when consumption was more than 7 g to equal to 15 g of chia seed daily; and (3) high dose when consumption was greater than 15 g of chia seed daily. To assess publication bias, Egger's test 18 (when more than 10 trials were included in the meta-analysis) was conducted to calculate the significance level of funnel plot asymmetry, where P < 0.10 indicates significant funnel plot asymmetry. 19 The software used for data analysis was Stata version 12 (StataCorp; College Station, Texas, USA).
Quality of evidence
The overall quality of evidence was assessed independently by 2 authors (S.L.T. and N.M.L.) using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, 20 which considers study design, risk of bias of individual trials, heterogeneity, directness of evidence, precision of effect estimates, and possibility of publication bias. 20 GRADEpro software version 3.6.1 (McMaster University; Hamilton, Ontario, Canada) was used to generate the summary of findings table. The overall quality of evidence ranged from high, to moderate, to low, to very low, where high quality indicates a high degree of certainty that the estimated effect lies close to the true effect, while very low quality indicates substantial uncertainty about the estimated effect. 21 
Sensitivity analysis
To ensure robustness of results, sensitivity analysis was performed by meta-analysis using a fixed-effects model when there was no heterogeneity 22 and by excluding the data of trials shown to be of low quality in the meta-analysis.
RESULTS

Study selection
The search yielded a total of 1123 articles: 1121 identified from electronic databases and 2 obtained by contacting the authors. A total of 252 duplicates were removed. Of the remaining 871 studies screened, only 25 were relevant and were retrieved for full-text review. Full-text review revealed only 14 studies that met the inclusion criteria. The 11 excluded studies were duplicates (n ¼ 3) or a review article (n ¼ 1), did not involve chia seed (n ¼ 2), were not randomized (n ¼ 2), did not have a comparator group (n ¼ 1), described a protocol only (n ¼ 1), or had inadequate information for data extraction (n ¼ 1). Thus, 14 trials involving 526 participants were included in this review. One trial 23 that assessed the effects of chia seed only on the chia seed group was not included in the meta-analysis. The flow diagram of study selection is shown in Figure 1 . The list of excluded studies is available in Table S2 in the Supporting Information online.
Study characteristics
The characteristics of the 14 included studies are summarized in Table 2 . [5] [6] [7] [8] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The trials were conducted
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Studies included in quantitative synthesis (meta-analysis) (n = 13) Figure 1 Flow diagram of the literature search process. in Canada (n ¼ 6), [5] [6] [7] [8] 24, 32 the United States (n ¼ 5), 23, [25] [26] [27] 31 Brazil (n ¼ 2), 28, 29 and Mexico (n ¼ 1). 30 24 was later published 7 with some data that was available only in the thesis; therefore, both trials 7, 24 were included. On a separate note, upon confirmation by the authors, 2 trials 28, 29 included were essentially the same study with same group of participants, but they investigated different clinical assessments. One trial 28 reported the clinical effects in separate intervention groups (ie, intervention groups who took and who did not take antihypertensive medication), while the other trial 29 reported the effects only in 1 group that included a combination of those who took and those who did not take antihypertensive medication. The participants in the comparator group reported in both trials 28, 29 all took antihypertensive medication. Therefore, to ensure comparability between groups, the comparison of clinical effects between intervention and comparator groups who took antihypertensive medication 28 was used as the main analysis if results of both trials 28, 29 were available. The total number of participants included in each trial was relatively small, ranging from 11 participants 8 to 97 participants. 32 Participants in the included trials ranged between 18 and 75 years of age, with the mean age being above 48 years (n ¼ 6), 5, 24, 28, 29, 31 ,32 below 40 years (n ¼ 5), 7, 8, 23, 26, 27 or not reported (n ¼ 3). 6, 25, 30 None of the trials assessed the effects of chia seed in children. The participants recruited were generally healthy, having no known disease in 6 trials, [6] [7] [8] 23, 25, 31 type 2 diabetes with a stable glycemic condition in 3 trials, 5, 24, 32 and risk factors for metabolic syndrome in 3 trials. [28] [29] [30] In 2 trials, 26,27 the participants were athletes. The most common form of chia seed used in the intervention group was chia seed incorporated into food or drink, used in 10 trials, [5] [6] [7] [8] 24, [27] [28] [29] 31, 32 followed by chia seed taken on its own in 2 trials, 23 ,25 a dehydrated mixture of chia seed and nopal, oat, and soybean protein in 1 trial, 30 and chia seed oil added to water in 1 trial. 26 Notably, 6 trials 5-8,24,32 used Salba chia seed. The daily quantity of chia seed consumed ranged from 4 g to 50 g in 13 trials, [5] [6] [7] [8] [24] [25] [26] [27] [28] [29] [30] [31] [32] though 1 trial 26 used calories as the unit of measurement, ie, 7 kcal/kg. 26 To enable comparability, the measurement was converted to grams using the US Department of Agriculture's estimation of 486 kcal per 100 g of chia seed 33 and the mean weight reported in the trial, 26 resulting in a daily quantity of 103 g of chia seed. 26 Complete details of chia seed and the comparators used are summarized in Table 2 . All of the included trials assessed outcomes on surrogate markers only and not on any type of clinical event. The most commonly assessed outcomes were glycemic measures (n ¼ 10), [5] [6] [7] [8] 24, 25, 28, 29, 30, 32 anthropometric measures (n ¼ 9), 5 28 and nitric oxide. 28 Trials that assessed outcomes related to athletic performance used shorter durations of chia seed intake of 2 days 26 and 14 days. 27 The other 3 trials 6-8 used a 1-day duration of chia seed intake and assessed postprandial blood glucose every 15 minutes up to 60 minutes, followed by assessment every 30 minutes up to 120 minutes. The remaining trials used a longer duration of intake that ranged from 35 days 23 to 168 days 24, 32 for other outcome assessments. In the majority of trials (n ¼ 11), 5, 7, [23] [24] [25] [27] [28] [29] [30] [31] [32] participants were instructed to control their diet during the trial, while 3 trials 6, 8, 26 did not report whether participants were instructed to control their diet.
Study quality assessment
Most of the trials (n ¼ 11) [5] [6] [7] [8] 23, 24, [28] [29] [30] [31] [32] were found to have an overall unclear risk of bias, and 2 trials had a high risk of bias. 25, 26 One trial 27 was available only as a conference abstract and therefore did not have sufficient information for quality assessment. Consequently, it was assessed to have an unclear risk of bias in this review.
For the sequence generation domain, more than half of the trials (n ¼ 8) [5] [6] [7] 24, 26, 28, 29, 32 were found to have a low risk of bias with an appropriate randomization method. Five trials 8, 23, 25, 30, 31 had an unclear risk of bias and lacked a description of the randomization method, even though "randomized" was described. For allocation concealment, half of the trials (n ¼ 7) [6] [7] [8] 23, 25, 26, 30 had an unclear risk of bias because they did not provide adequate information. Six trials 5, 24, 28, 29, 31, 32 concealed the allocation sequence using an appropriate method and had a low risk of bias. For the blinding domain, all trials were found to have either an unclear or a high risk of bias. Of the 11 trials with an unclear risk of bias, [5] [6] [7] [8] 23 ,24,28-32 6 trials 6, 8, 23, 28, 29, 31 mentioned "double-blind" but provided no description of the method. Although the other 5 trials 5, 7, 24, 30, 32 endeavored to ensure both the appearance and the taste of chia seed and the comparator were the same, there was no test to clarify whether the blinding was successful. Two trials 25, 26 had a high risk of bias: 1 of these 26 described "no blinding" and the other 25 described that the blinding was highly likely broken. For the incomplete outcome data domain, almost all of the trials assessed (n ¼ 12) [5] [6] [7] [8] [23] [24] [25] [28] [29] [30] [31] [32] had adequately reported the reason for withdrawals or dropouts from the trials. The other trial 26 had no description about the withdrawals or dropouts and thus had an unclear risk of bias. As for the selective reporting domain, all trials reported all the prespecified outcomes.
For the other sources of bias domain, half of the trials had a low risk of bias and the other half had an unclear risk of bias. Of the trials with a low risk of bias, 5 trials 8,28-31 were not funded and declared no conflict of interest, and another 2 trials 24, 32 were funded by a Canadian Diabetes Association operating grant, which was not considered to have introduced bias. Of the trials with an unclear risk of bias, 2 trials 5,23 did not describe the funding, 1 trial 25 was funded by market research and a nonprofit research institute (ie, Nutritional Science Research Institute, Marlborough, Massachusetts, USA), 2 trials were funded by chia seed companies that included the Dole Food Company (Westlake Village, California, USA) 26 and Salba Smart Natural Products (Littleton, Colorado, USA), 6 and 1 trial used an employee of a chia seed company to assist in the manuscript preparation. 7 The risk-of-bias assessment of the included trials is summarized in Table 3 , [5] [6] [7] [8] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] with further details provided in Table S3 in the Supporting Information online.
Clinical effects of chia seed
Anthropometric outcomes. There were no significant differences in any of the anthropometric parameters between participants who received chia seed and the control group, except for gynoid fat. These included pooled MDs for the following: (1) 28, 30, 32 all with no heterogeneity (I 2 ¼ 0.0%, P > 0.10). The effects on hip circumference and android fat were not significant, with an MD of À2.90 cm (95%CI, À7.36 to 1.56; 1 trial; GRADE low) 24 and À0.18% (95%CI, À4.82 to 1.22; 1 trial; GRADE low), 32 respectively, while the effect on gynoid fat was significant, with an MD of À5.20% (95%CI, À10.24 to À0.16; 1 trial; GRADE low), 32 with all effects assessed by single trials. The effect estimates are summarized in Table 4 , [5] [6] [7] [8] [24] [25] [26] [27] [28] [29] [30] [31] [32] and forest plots are shown in Figure S1 in the Supporting Information online. Subgroup analysis showed that the lack of statistical significance in all anthropometric parameters remained unchanged (Table 5 5-8, [24] [25] [26] [28] [29] [30] [31] [32] ). However, participants who were overweight/obese appeared to have a nonsignificantly higher body weight gain and a nonsignificantly higher body fat mass gain compared with those with health conditions who were also overweight/obese (Table 5 ). In addition, participants who took ground chia seed appeared to have nonsignificantly less body weight gain and more body fat reduction compared with those who took whole chia seed. However this finding was based only on the effect reported in 1 trial that recruited overweight/obese participants and used whole chia seed. 27 Details of the GRADE quality of evidence are shown in Table 6 . Forest plots of subgroup analyses are provided in Figure S2 in the Supporting Information online.
Glycemic outcomes. There were no significant differences in any of the glycemic parameters between 30 Nieman et al (2012) 31,c Brissette (2013) 24 Toscano et al (2014) 28 5, 24, 30 all with no or minimal heterogeneity (I 2 ¼ 0.0%, P > 0.10). Postprandial blood glucose was also nonsignificantly different, with a pooled MD of À24.10 incremental area under the curve (iAUC) (mmol/L Â 2 h) (95%CI, À53.08 to 4.87; 4 trials; I 2 ¼ 67.9%, P ¼0.025; GRADE very low). [6] [7] [8] 30 Of all the subgroup analyses, the one assessing the reduction of postprandial blood glucose was found to be significantly different for the following: (1) high and medium doses of chia seed, (2) participants with a healthy body mass index, and (3) Salba chia seed (Table 5) . Moreover, 2 additional subgroup analyses were conducted on postprandial blood glucose for trials using diet control 7, 30 or not 6, 8 and for trials using different times of assessment. [6] [7] [8] 30 The reduction in postprandial blood glucose was not significant for trials that did not report whether the participants' diet was controlled or not 6, 8 as well as for trials that reported controlled diets. 7, 30 However, the reduction in postprandial blood glucose was significant for trials that assessed the effect within the same day (À38. 15 Markers of inflammation. There were no significant differences in any of the markers of inflammation between participants who received chia seed and the control group. These included pooled MDs with no heterogeneity (I 2 ¼ 0%, P > 0.10) for the following: (1) C-reactive protein, À0.61 mg/L (95%CI, À1.36 to 0.14; 5 trials; GRADE low), 5, 28, [30] [31] [32] (2) interleukin 6: < 0.001 pg/mL (95%CI, À0.01 to 0.02; 3 trials; GRADE low), 25, 26, 31 (3) interleukin 8: À0.73 pg/mL (95%CI, À2.57 to 1.10; 2 trials; GRADE low), 26 ,31 (4) interleukin 10, À0.28 pg/mL (95%CI, À2.23 to 1.66; 2 trials; GRADE low), 26, 31 and (5) tumor necrosis factor a, < 0.001 pg/mL (95%CI, < À0.001 to 0.01; 3 trials; GRADE low). 25, 26, 31 The pooled MD was also not significant for von Willebrand factor: À0.09 IU/mL (95%CI, À0.32 to 0.14; 2 trials; GRADE low), 5, 24 with minimal heterogeneity of I 2 ¼ 25.2%, P ¼ 0.247. Other MDs of inflammatory markers, including acid glycoprotein, factor VIII, fibrinogen, leukocytes, and plasma monocyte chemotactic protein, reported by single trials were all not significant and were assessed as GRADE low (Table 4) . The lack of statistical significance remained unchanged in subgroup analysis ( Table 5) . The additional subgroup analysis on diet control during the trials also did not One trial assessed the effect of both whole and ground chia seed. Android fat (follow-up: 168 days) Mean android fat in intervention group was 1.80% lower Heart rate (follow-up: 1 day) Mean heart rate in intervention group was 2.00 beats/min lower change the lack of statistical significance (where the result of 1 trial that did not instruct participants to control their diet 26 was the same trial that included athlete participants, while the 2 trials that did instruct participants to control their diet 25, 31 were the same trials that included overweight and obese participants). However, athlete participants who did not control their diet during trials appeared to have a greater reduction in markers of inflammation (interleukins 6, 8, and 10 and tumor necrosis factor a) compared with nonathlete participants who did control their diet (Table 5) . Again, however, the findings are based on only 1 trial. 26 Lipid outcomes. There were no significant differences in any of the lipid parameters between participants who received chia seed and the control group. These included the pooled MDs for the following: (1) total cholesterol, 0.07 mmol/L (95%CI, À0.30 to 0.15; 6 trials; GRADE low), 5, 24, 25, 28, 30, 31 (2) low-density lipoprotein, À0.01 mmol/L (95%CI, À0.24 to 0.21; 5 trials; GRADE low), 5, 24, 25, 28, 30 (3) high-density lipoprotein, À0.05 mmol/L (95%CI, À0.11 to 0.02; 5 trials; GRADE low), 5, 24, 25, 28, 30 and (4) triglyceride, À0.08 mmol/L (95%CI, À0.32 to 0.17; 5 trials; GRADE low), 5, 24, 25, 28, 30 all with either no or minimal heterogeneity. One trial also assessed the effect of chia seed on very low-density lipoprotein. 28 The MD was not significant: À2.00 mg/ dL (95%CI, À22.25 to 18.25; GRADE low). The lack of statistical significance remained unchanged in subgroup analysis, except for the effect of chia seed on highdensity lipoprotein (Table 5 ). The results of 3 trials that used high doses of chia seed and whole chia seed 5, 25, 28 were significant, with pooled MDs of À0.10 (95%CI, À0.20 to À0.01; I 2 ¼ 0.0%, P ¼ 0.403) (3 trials 5, 25, 28 ) and 0.16 (95%CI, À0.30 to 0.62) (1 trial 25 ), respectively. On another note, interestingly, when high doses of chia seed were used, the effect appeared to be less favorable on all lipid parameters, ie, increased total cholesterol, low-density lipoprotein, and triglyceride and decreased high-density lipoprotein, than when low or medium Rating of evidence quality, according to GRADE. High represents a high degree of confidence that the true effect lies close to that of the estimate of the effect. Moderate represents a moderate degree of confidence in the effect estimate, ie, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low represents limited confidence in the effect estimate, ie, the true effect may be substantially different from the estimate of the effect. Very low represents very little confidence in the effect estimate, ie, the true effect is likely to be substantially different from the estimate of effect. b All trials with either unclear or high overall risk of bias, as well as some trials with unclear selection bias. This created some uncertainty about the reliability of the results, even though most outcomes assessed were objective outcomes. doses were used. In addition, the lipid-lowering effect appeared to be greater for participants with a health condition than for participants without a health condition for all lipid parameters, for Salba chia seed compared with non-Salba chia seed for total cholesterol and low-density lipoprotein, and for ground chia seed compared with whole chia seed for all lipid parameters.
Blood pressure. There were no significant differences for either diastolic blood pressure or systolic blood pressure between participants who received chia seed and the control group. The pooled MD for diastolic blood pressure was À3. (Table 5) , although ground chia seed was found to have a greater effect on reduction of systolic blood pressure compared with whole chia seed.
Markers of liver and renal function. There was no significant difference for either liver markers or renal markers between participants who received chia seed and the control group. For liver markers, no parameters were significant, with the pooled MD being À0.10 U/L (95%CI, À3.29 to 3.08; 2 trials; GRADE low; I 2 ¼ 0%, P > 0.828) 5,24 and 3.39 U/L (95%CI, À1.82 to 8.60; 2 trials; GRADE low; I 2 ¼ 20.2%, P ¼ 0.263) for aspartate aminotransferase 5, 24 and alanine aminotransferase, 5, 32 respectively. Alkaline phosphatase was also assessed by 1 trial 24 ; the MD was nonsignificant and the GRADE low (Table 4) . No significant change in findings was found in subgroup analysis.
For renal markers, neither creatinine nor blood urea nitrogen had a significant pooled MD. The MD for creatinine was À1.37 lmol/L (95%CI, À7.42 to 4.69; 2 trials; GRADE low), 5, 32 with no heterogeneity, and for blood urea nitrogen À0.28 mmol/L (95%CI, À1.30 to 0.74; 2 trials; GRADE low), 5, 32 with substantial heterogeneity of I 2 ¼ 54.9%, P ¼ 0.137. In the case of blood urea nitrogen, the source of heterogeneity could be the dose of chia seed, as 1 trial 5 used a high dose of chia seed and another trial 32 used a medium dose. Separating the pooled analysis resulted in nonsignificant MDs for the individual trials (Table 5 ). The lack of statistical significance remained unchanged in subgroup analysis.
Markers of athletic performance. There was no significant difference for all but one of the athletic-related parameters between participants who received chia seed and the control group. The MDs for time and distance to exhaustion, 26 volume of oxygen consumption, 26 ventilation, 26 rating of perceived exertion, 26 respiratory exchange ratio, 26 plasma volume shift, 26 lactate, 26 glucose, 26 time to complete a 15-km trial, 27 and average power output 27 were all nonsignifcant; only the MD for heart rate was significant (Table 4) . 26 Evidence for all parameters was GRADE low. The MD for heart rate was significant, with À2.00 beats per minute (95%CI, À361 to À0.39), GRADE low. 26 It should be noted, however, that the effect estimate of glucose assessed by 1 trial 26 was not combined with the effect estimates of the other 8 trials 5, 6, 8, 24, 25, 28, 30, 31 summarized in glycemic parameters, as the regimens employed were intrinsically different.
Other parameters. There were no significant differences between participants who received chia seed and the control group for all other parameters related to hemostasis 24 (except for prothrombin time 24 ), for satiety or glucose-regulating hormone 24, 30, 32 (except for ghrelin 32 ), oxidative stress, 28 cortisol, 26 and nitrite, 28 and for appetite measurements 7, 8 (except for 1 measurement 8 ); evidence in all cases was GRADE low. The MDs for ghrelin and prothrombin time were significant: À211.40 seconds (95%CI, À361.83 to À60.97; 1 trial; GRADE low) 32 and À0.30 seconds (95%CI, À0.58 to À0.02; 1 trial; GRADE low), 24 respectively, while for appetite the MD was less than À0.001 min Â mm (total of 2 h) (95%CI, < À0.001 to À2.98; 1 trial; GRADE low) 8 at a high dose (24 g/d) of chia seed intake (Table 4) .
Adverse effects. Nine of the 14 included trials [5] [6] [7] 24, 25, 28, 29, 31, 32 assessed the adverse effects of chia seed, while the other 5 trials 8, 23, 26, 27, 30 did not report whether adverse effects were assessed. Of the 9 trials that assessed adverse effects, 2 reported no adverse effects. 6, 7 The other trials reported gastrointestinal adverse effects (5 of 9), 5, 24, 28, 31, 32 difficulty in adhering to the regimen (1 of 9), 25 mental adverse effects (1 of 9), 31 and hepatic/renal disorder (1 of 9), 28 all with no significant differences between the participants who received chia seed and the control group. One trial did not report the results of adverse effects assessment. 29 Sensitivity analysis It was not possible to perform a sensitivity analysis by excluding the data of trials with low quality from the meta-analysis because a limited number of trials were pooled and because all trials were of low quality (high or unclear risk of bias).
DISCUSSION
To the extent of the authors' knowledge, this is the first systematic review that has included a meta-analysis component to estimate the effect size of chia seed on a number of parameters used to assess human health. The meta-analysis showed the pooled effects of chia seed on all parameters measured to be nonsignificant in main analysis. However, in subgroup analysis, the pooled effects on postprandial blood glucose, high-density lipoprotein, and diastolic blood pressure were significant when higher doses of chia seed were used. There was considerable uncertainty about the magnitude of the possible effects, although it appeared that the effects, if present, were at best modest and were probably not clinically significant. In addition, all trials included in the review employed surrogate markers as outcomes, making the findings less clinically meaningful.
The findings of this review were consistent with the results of a systematic review and meta-analysis of flaxseed, whose high alpha-linolenic acid content is similar to that of chia seed. 34 Like that systematic review and metaanalysis, the current review found that diastolic blood pressure was significantly lower postconsumption. However, in contrast to that systematic review and metaanalysis, 34 the present review showed that the effect of chia seed to reduce systolic blood pressure was not significant. Nevertheless, given the uncertainty about which main active ingredient of chia seed contributes to its health effects, the comparison with flaxseed was only to provide a reference to the food most similar to chia seed. This review reveals that there was a lack of a suitable comparator used in most of the trials that employed active comparators (including wheat, oat, and poppy seed). This may have resulted in the lack of clinical benefits for the assessment. In addition, a few studies reported "nothing given" in the comparator group, which may have introduced performance bias in the trials by failing to blind the participants. Nevertheless, all trials in this review were assessed to have unclear or high risk of bias, and subgroup analysis was conducted to assess the effect of the use of active and nonactive comparators. Future trials should aim to achieve adequate blinding of participants by including a test to check whether participant blinding was successful.
The subgroup analysis that compared the clinical effects of Salba chia seed with those of conventional chia seed revealed no significant difference between the two. A number of glycemic and lipid parameters, however, showed an increased likelihood for trials that used Salba chia seed to report more favorable effects compared with trials that used conventional chia seed. Since all of the trials that used Salba chia seed had an unclear risk of bias when assessed in the subgroup analysis, it remains uncertain whether the more favorable effects reported with Salba chia seed are attributable to the type of chia seed used or to other factors. Future trials to compare the clinical effects between the two types of chia seeds are warranted. In addition, it is important that future trials report any potential conflict of interest to prevent potential bias.
The subgroup analysis also generated a number of hypotheses, including the possibility that higher doses of chia seed may result in greater clinical effects, including the lowering of postprandial blood glucose (statistically significant and in favor of chia seed) and the increasing of total cholesterol, low-density lipoprotein, and triglyceride and the lowering of high-density lipoprotein (all nonsignificant and not in favor of chia seed). The selection of participants and the dosage of chia seed may also influence the clinical effects of chia seed, as overweight/obese participants had greater body weight gain and greater body fat mass gain compared with those with health conditions who were also overweight/obese, while participants with health conditions showed greater improvement in lipid parameters compared with those without health conditions. Finally, ground chia seed resulted in more favorable outcomes for systolic blood pressure, fasting blood glucose, and anthropometric and lipid parameters compared with whole chia seed; however, only whole chia seed had a significant effect on the reduction of postprandial blood glucose. Importantly, the hypotheses generated were based on single trials or on trials with an unclear or high risk of bias. In addition, while trials were grouped according to homogenous characteristics for one of the specific characteristics, other PICOS parameters may have substantial heterogeneity. Therefore, the hypotheses must be further investigated in rigorously conducted studies.
As with any systematic review and meta-analysis, this review shares the limitations of the original trials. First, a major issue is that all trials were found to have very low quality of evidence (all had either an unclear or a high risk of bias). Results were imprecise when the sample size was less than 400 for all outcomes assessed and the confidence interval included both clinically important benefits and clinical harm, or both clinically important effects and null effects. The overall very low quality of evidence based on the GRADE approach indicates that findings should be interpreted with caution. Other systematic reviews and meta-analyses of herbal 35 and food 36 products have noted similar issues with quality of evidence. In light of this, future trials should aim to improve the methodological quality by ensuring adequate blinding, randomization, and allocation concealment; by clearly reporting any potential conflict of interest, as highlighted in the risk-of-bias assessment; and by using sample sizes of at least 400 to increase precision. 37 Second, all trials included in this review used only surrogate markers to measure outcomes. Although the use of surrogate markers is more efficient for conducting clinical trials, it may have limited value in predicting clinical benefit, especially for long-term clinical outcomes. 38 Future trials should use clinical events as outcomes or should validate the surrogate markers by demonstrating a clear association with the clinical outcomes. 39 Third, to provide plausible effect estimates and pose new questions about the clinical effects of chia seed with exploratory meta-analysis, 40 the data were pooled from individual studies with broadly similar characteristics in terms of population and intervention. 41 Fourth, although an exhaustive literature search was performed and an effort was made to include gray literature, there might be unpublished studies that were missed. Lastly, publication bias could not be reliably assessed by funnel plots or other means, owing to the small number of included studies.
CONCLUSION
This review provides crucial information for healthcare providers and the public to understand the current evidence regarding health claims for chia seed. The current evidence does not support any health claim for chia seed in any indication. Nevertheless, this systematic review and exploratory meta-analysis has generated hypotheses for future studies to investigate the effects of chia seed on a dose-response gradient. The use of reputable methodological tools for quality assessment (Cochrane Risk of Bias Tool and GRADE) in this review has identified methodological gaps that provide a reference for the design of future high-quality randomized controlled trials to evaluate the clinical effects of chia seed.
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